WHC is still in active development. Read this to understand our approach.
depiction of JEYCTXHKTXCGPB-UHFFFAOYSA-N.svg
tripsit

ethaqualone

Verificar en tripsit

tripsit

methaqualone

Verificar en tripsit

psychonaut

Methaqualone

Verificar en psychonaut

isomerdesign

Methaqualone

Verificar en isomerdesign

pubchem

Methaqualone

Verificar en pubchem

druglab

Méthaqualone

Verificar en druglab

drugmap

Methaqualone

Verificar en drugmap

Data

InChI: InChI=1S/C16H14N2O/c1-11-7-3-6-10-15(11)18-12(2)17-14-9-5-4-8-13(14)16(18)19/h3-10H,1-2H3

Sinónimos: Optimil, Parest,Hypcol,Methased,C07560,CN-38703,Nobedorm,CN 38703,Dormigoa-Schlafmittel,Metaqualon,METHAQUALONE [USAN],Parminal,2-Methyl-3-(2-methylphenyl)-4(3H)-quinazolinone,Normi-Nox,Dormogen,MTQ,HMS2626L18,METHAQUALONE [EP IMPURITY],DSSTox_GSID_23279,TR-495, 2-Methyl-3-(o-tolyl)-4-quinazolone hydrochloride,NCGC00245236-01,UNII-7ZKH8MQW6T,Methaqualone solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Mozambin hydrochloride,AKOS000509786,Fadormir,MLS000678342,CHEMBL282052,Sonal,Ipnofil,Motolon,Methaqualone 0.1 mg/ml in Methanol,Mozambin,Metolquizolone,Tuazolone,2-Methyl-3-(2-tolyl)quinazol-4-one,DTXCID403279,4(3H)-Quinazolinone, 2-methyl-3-o-tolyl-,Somberol,METHAQUALONE [MI],7ZKH8MQW6T,Rorer 714,Optinoxan, Somnofac,Q423912, TR 495 monohydrochloride,SCHEMBL43892,Tuazol,Rorer 148, NSC 75892,Metachalon,quaaludes,DSSTox_CID_3279,Nethaqualone,2-Methyl-3-o-tolyl-4(3H)-chinazolone,R-148,STL386501,NSC-111388-,2-Methyl-3-o-tolyl-4(3H)-chinazolinon [German], Sopor hydrochloride,2-Methyl-3-(o-tolyl)quinazolin-4(3H)-one,Citexal,ludes,DEA No. 2565, Methylquinazolone hydrochloride,HSDB 3120, 2-Methyl-3-tolylchinazolon-4 hydrochloride [German],Dormutil,METHAQUALONE,METHAQUALONE [MART.], MTQ hydrochloride,METHAQUALONE [WHO-DD],Melsomin,Melsed,J-511183,Roulone, Mequal,SMR000285241,2-methyl-3-(2-methylphenyl)quinazolin-4(3H)-one,Dorsedin,2-Methyl-3-o-tolyl-4(3H)-quinazolinone,Metakvalon,etaqualone,NSC-631628, Somnafac, Melsedin, Methaqualone HCl,2-methyl-3-(o-tolyl)-quinazoline-4 (3H)-one,Hypocol,Hyptor base,METHAQUALONE [INN],CHEBI:6821,2-methyl-3-(o-tolyl)-3H-quinazolin-4-one,BRN 0211874,(.+/-.)-Methaqualone,CI-705,Hyptor, UNII-RJQ4G25ZRH,Methaqualone 1.0 mg/ml in Methanol,MQL, EINECS 206-431-2,DB04833,NSC111388,METHAQUALONE [VANDF],Mequin,Methaqualone,LS40046, RJQ4G25ZRH,Pro-dorm,5-24-03-00132 (Beilstein Handbook Reference),Cateudyl,2-methyl-3-(2-methylphenyl)quinazolin-4-one,Melsedin base,4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)-, (-)-,Noctilene,4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)-,Dormigoa,Sopor,DSSTox_RID_76954,Methaqualonum [INN-Latin],Tox21_112502,2-Methyl-3-(2-methylphenyl)-4-quinazolinone,NSC126877,Ortonal,D00557,RIC 272,METHAQUALONE [HSDB],Rouqualone, CHI 38,Aqual,2-Methyl-3-o-tolyl-4-quinazolone,Somnomed, Melsed HCl,ZINC2568176,WLN: T66 BVN ENJ CR B1& D1,MAOA,NSC-126877,4(3H)-Quinazolinone, 2-methyl-3-o--tolyl-,QZ-2,NCGC00245236-02,Somnafac,Quaalude,CI 705,Methaqualone hydrochloride,3,4-Dihydro-2-methyl-4-oxo-3-o-tolylquinazoline, 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)-, monohydrochloride,Methaqualone [USAN:USP:INN:BAN],NSC-111388,Soverin,2-Methyl-3-(o-tolyl)-3,4-dihydro-4-quinazolinone,2-methyl-3-(o-tolyl)quinazolin-4-one,QZ 2,Torinal,mandrax,2-Methyl-3-tolyl-4-oxybensdiazine,Sindesvel,2-Methyl-3-o-tolylquinazolin-4-one,NSC631628,Methaqualon,Omnyl,Metacualona [INN-Spanish],Hyminal,Mollinox,Orthonal,Tuazole,DTXSID7023279,CAS-72-44-6,Revonal,METHAQUALONE [JAN],Reposil, 340-56-7,2-Methyl-3-o-tolyl-4(3H)-chinazolinon,Holodorm,Tox21_112869,EINECS 200-780-4,Methaqualoneinone,NSC 111388,72-44-6, Quaalude hydrochloride, Hyminal monohydrochloride,Metachalon [Czech],TR 495,qualudes,(2-Methyl-3-(o-tolyl)-3,4-dihydro-4-(quinazolinone)


Estimated data

Solubilidad: -4.469 (log(S) in mol/L prediction using SolTranNet)

Addictivity Prediction: 79.1% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.